These patients receive chemotherapy to shrink their tumor, making it easier to surgically remove. This trial assessed adding an infusion of the drug nivolumab—or a placebo—to the pre-surgery phase and ...
For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 ...
GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Elizabeth Plimack discussing two abstracts: “Adjuvant nivolumab vs placebo for high-risk ...
Opdivo contains the medicine nivolumab. It acts on proteins on the ... metastatic or has come back during or after treatment with chemotherapy. Opdivo is put into a vein as an intravenous (IV ...
Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...
Dr Zaheer Mangera discusses the evolution of the neoadjuvant lung cancer pathway and notable changes to the TNM standards.
Thus, it seemed a reasonable strategy to investigate the combination of neoadjuvant nivolumab and nab-paclitaxel ... receive neoadjuvant cisplatin-based chemotherapy, there could be opportunities ...
Adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback